key: cord-0307072-vvm2gusm
authors: YULUG, B.; ALTAY, O.; LI, X.; HANOGLU, L.; CANKAYA, S.; LAM, S.; YANG, H.; COSKUN, E.; IDIL, E.; NOGAYLAR, R.; BAYRAM, C.; BOLAT, I.; ONER, S.; TOZLU, O. O.; ARSLAN, M. E.; HACIMUFTUOGLU, A.; YILDIRIM, S.; ARIF, M.; ZHANG, C.; NIELSEN, J.; TURKEZ, H.; BOREN, J.; UHLEN, M.; MARDINOGLU, A.
title: Combined Metabolic Activators Improves Cognitive Functions in Alzheimer's Disease
date: 2021-07-20
journal: nan
DOI: 10.1101/2021.07.14.21260511
sha: e6fc0224b805699dc79fdc8e4e0bae29c9be6996
doc_id: 307072
cord_uid: vvm2gusm

Alzheimer's disease (AD) is associated with metabolic abnormalities linked to critical elements of neurodegeneration. Here, we analyzed the brain transcriptomics data of more than 600 AD patients using genome-scale metabolic models and provided supporting evidence of mitochondrial dysfunction related to the pathophysiologic mechanisms of AD progression. Subsequently, we investigated, in an animal model of AD, the oral administration of Combined Metabolic Activators (CMAs), consisting of NAD+ and glutathione precursors, to explore the effect for improvement of biological functions in AD. CMAs includes L-serine, nicotinamide riboside, N-acetyl-L-cysteine, and L-carnitine tartrate, salt form of L-carnitine. The study revealed that supplementation of the CMAs improved the AD-associated histological parameters in the animals. Finally, we designed a randomized, double-blinded, placebo-controlled human phase 2 study and showed that the administration of CMAs improves cognitive functions in AD patients. A comprehensive analysis of the human plasma metabolome and proteome revealed that plasma levels of proteins and metabolites associated with redox metabolism are significantly improved after treatment. In conclusion, our results show that treating AD patients with metabolic activators leads to enhanced cognitive functions, suggesting a role for such a therapeutic regime in treating AD and other neurodegenerative diseases.

Alzheimer's disease (AD) is characterized by progressive synaptic and axonal dysfunction, neuronal loss and cognitive decline 1 . There is growing evidence that AD is closely associated with metabolic and oxidative stress linked to critical elements of neurodegeneration, such as mitochondrial dysfunctions and bioenergetic impairments 2, 3 . Indeed, increasing data indicate that systemic metabolic disorders, such as insulin resistance, are strongly associated with bioenergetic failure of nerve cells 4, 5 . This can manifest as cognitive impairment and brainspecific neuropathology while sharing common pathogenic mechanisms with AD, such as impaired glucose metabolism, increased oxidative stress, insulin resistance, and amyloidogenesis 4, 6, 7 . Recent evidence accordingly suggests that patients with type 2 diabetes mellitus are at increased risk of developing AD 6 .

Although the disease is still defined by the accumulation of abnormal amyloid and tau proteins 8 , the mechanistic assumption of linear causality between the amyloid cascade and cognitive dysfunction in AD is flawed, since amyloid-lowering approaches have failed to provide cognitive benefits in human clinical trials 9 . A growing body of evidence suggests that impaired brain energy metabolism in AD may contribute to cognitive decline. At the same time, therapeutic options, such as drugs typically prescribed for metabolic disorders that improve metabolic status, may slow cognitive decline or prevent dementia progression 10 . This is suggested by positron emission tomography imaging studies revealing baseline cerebral glucose metabolism abnormalities before the onset of cognitive symptoms in patients with AD 11 . In addition, recent preclinical data indicate that ageing and AD are associated with the reorganization of brain energy metabolism, including an overall increase in lactate secretion and the downregulation of bioenergetic enzymes 12, 13 .

Although current research is paving the way for developing neuroprotective therapeutics, the results of early clinical trials of drugs targeting single pathways have been mostly unsuccessful. A divergent approach combining multiple compounds that simultaneously reduce oxidative injury and improve bioenergetics, in other words, targeting various pathways has been proposed as a therapeutic strategy associated more likely with successful translational outcomes 14 . Previous research identified limited serine availability, reduced de novo glutathione synthesis, and altered NAD+ metabolism based on the combining multiomics profiling of transgenic AD mouse model of AD 15 . Consistent with this, it also has been reported that age-and AD-associated metabolic shifts responded well to NAD(P)+/NAD(P)H redox-dependent reactions 16, 17 . These findings were confirmed by human metabolomic data showing significantly altered cerebrospinal fluid (CSF) acylcarnitine levels in patients with AD, which correlated with the decline of cognitive functions and structural brain abnormalities 18, 19 .

Based on integrative network analysis of non-alcoholic fatty liver disease multi-omics data, we have developed a mixture combined metabolic activators (CMAs) consisting of L-serine, N-acetyl cysteine (NAC), nicotinamide riboside (NR), and L-carnitine tartrate (LCAT, the salt form of L-carnitine) and showed that administration of CMAs activates mitochondria, improves inflammation markers in animals and humans [20] [21] [22] [23] [24] . We have also found that the administration of CMAs promotes mitochondrial fatty acid uptake from the cytosol, facilitates the fatty acid oxidation in the mitochondria, and alleviates oxidative stress 25 . Recently, we reported that CMAs administration effectively increased fatty acid oxidation and de novo glutathione generation, as evidenced by metabolomic and proteomic profilings 20 . Moreover, plasma levels of metabolites associated with antioxidant metabolism and inflammatory proteins were improved in COVID-19 patients treated with CMAs compared to the placebo 24 .

Here, we first analyzed brain transcriptomics data obtained from 629 AD patients and 704 control subjects using genome-scale metabolic models and revealed that mitochondrial dysfunction is involved in the underlying molecular mechanisms associated with AD. Second, we tested the effect of CMAs, which has been shown to activate mitochondria in the AD animal model and showed that supplementation of the CMAs improved the AD and associated functions. Next, we hypothesized that AD patients could be treated with the administration of the CMAs by activating the mitochondria in the brain tissue of the patients.

Finally, we designed a randomized, double-blinded, placebo-controlled human phase 2 clinical study and showed that administration of CMAs improves the cognitive functions in AD patients.

To identify the metabolic dysregulations based on brain transcriptomics data, we obtained the global mRNA expression profiling of 629 AD patients and 704 controls from the Religious Orders Study/Memory and Aging Project (ROSMAP) [26] [27] [28] . We performed differential expression analysis and identified 914 and 1725 significantly upregulated and downregulated differentially expressed genes (DEGs) ( Figure 1A , Dataset S1). We identified several upregulated metabolism-related genes, including pyruvate dehydrogenase kinase 4 (PDK4), carnitine palmitoyl transferase (CPT1A), hexokinase 2 (HK2), and spermine oxidase (SMOX), as well as downregulated genes including acyl-CoA dehydrogenases (ACADs), ATP synthase (ATP5MGL), and acetyl-and acyltransferases (GCNT7, MBOAT4, GALNT17). These results suggest that there may be changes associated with glycolysis, the urea cycle, and fatty acid biogenesis in AD compared to control.

The gene set enrichment (GSE) analysis revealed that these DEGs were significantly enriched in the protein synthesis, ATP synthesis, lipid metabolism, cell cycle, cell migration, cell differentiation and cell adhesion pathways ( Figure 1B , Dataset S1). Then, we performed reporter metabolite analysis to predict the significantly changed metabolites in each subcellular compartment using a genome-scale metabolic model of brain tissue 29 . We identified numerous reporter metabolites related to glycolysis, amino acid metabolism (e.g. glycine, serine, threonine, alanine and branched-chain amino acid valine, leucine and isoleucine), mitochondrial function (acyl-CoA and ferredoxin) and TCA cycle (e.g. succinate and glutamine) ( Figure 1C and 1D, Dataset S1). These results suggested a widespread perturbation in energy metabolism related to brain cell survival and mitochondrial dysfunction in the brain.

To test the effect of CMAs in animals, we provided individual metabolic activators and

CMAs to the rat model of AD which has been developed after feeding the animals with high fat diet (HFD) and intracerebroventricular-streptozotocin (STZ) injection. We observed that administration of all constituents of CMAs (in combination or separately) significantly (p<0.05) decreased the plasma levels of triglycerides (TG) compared to the control group (Group 4; Figure 2A , Dataset S2). In parallel, administration of only serine or NR significantly decreased total cholesterol (p=0.01) and low-density lipoprotein (LDL; p=0.03) in rats ( Figure 2B , Dataset S2). Additionally, a significant reduction in total cholesterol (p=0.04) and LDL (p=0.03) was observed with NAC-treated and LCAT-treated rats, respectively ( Figure 2B , Dataset S2). Of note, we found significant reductions in plasma AST (p=0.03) and an increase in plasma ALP (p=0.04) concentrations only in LCAT-treated rats (Group 8) ( Figure 2B , Dataset S2).

Additionally, the histological analyses and immunofluorescence imaging techniques showed a significant neuronal tissue damage in the HFD and HFD+STZ groups' brains compared to those of the chow diet group ( Figure 2C , Dataset S2). Specifically, the HFD groups developed more hyperemia as well as more degeneration and necrosis in neurons ( Figure 2C , Dataset S2). In parallel, DNA damage markers (namely 8-OHdG and H2A.X) and caspase 3 were elevated in the HFD groups ( Figure 2C , Dataset S2). These animal models allowed us to examine each rat group's histopathological differences and assess the brain tissue response to CMAs administration compared to the HFD+STZ group ( Figure 2C , Dataset S2). We observed that hyperemia, degeneration and necrosis in neurons were improved by serine, LCAT, or NR supplementation individually as well as in combination. However, we observed a better improvement after the administration of CMAs compared to individual metabolic activators. These findings were also supported by immunohistochemical evidence of decreased immunoreactivity seen in neurons ( Figure 2C , Dataset S2). Of note, rats receiving combination therapy (consisting of serine, NAC, LCAT and NR) developed less hyperemia in brain tissue and no necrosis in neurons ( Figure 2C , Dataset S2). In parallel to the improvement in the brain, we also observed dramatic improvement in the liver after the supplementation of CMAs. Scoring of histopathological, immunohistochemical and immunofluorescence findings for brain and liver tissues are presented in Table 1 .

To test the effect of the CMAs in AD patients, we performed a double-blind, randomized, placebo-controlled phase 2 study and screened 89 adults diagnosed with AD. We recruited 69 patients older than 50 years with mild to moderate AD according to ADAS-Cog (AD Assessment Scale-cognitive subscale; ADAS≥12) and the Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB; CDR≤2). Of the 69 patients, 47 were randomly assigned to the CMA group and 22 to the placebo group and completed visit 1 after 28 days. Of these patients, 60 (40 in the CMA group and 20 in the placebo group) completed visit 2 after 84 days ( Figure 3A , Dataset S3). We assessed the clinical variables on Days 0, 28 and 84, and analyzed the differences between the time points in the CMA and placebo groups (Dataset S4).

The patients' mean age participated in the study was 70.8 years (56-86 years), and 52.1 % were men (Dataset S4). The baseline demographic and clinical characteristics were similar in the CMA and placebo groups (Dataset S4). Regarding safety, no severe adverse events occurred and 4 patients (5.8 %) reported adverse events. All had a mild rash on the body and decided to complete the study (Dataset S3).

We measured clinical variables in all patients and analyzed the differences before and after administration in the active and placebo groups ( Figure 3B , Dataset S4). We observed a significant decrease of ADAS-Cog scores between different time points in both CMA and placebo group. Importantly, it showed a greater decrease in CMA group. We also analyzed the differences between clinical parameters by stratifying the patients into mild and severe ADAS-Cog groups (>20ADAS-Cog score is severe, ≤ 20 is mild). More interestingly, we found a significant difference of ADAS-Cog scores between different time points in the high scored CMA group and no difference in the high scored placebo group ( Figure 3B , Dataset S4), suggesting that the AD patients with high ADAS-Cog scores are more responsive to CMA.

Analysis of secondary outcome variables showed that serum alanine aminotransferase (ALT) levels were significantly lower on Day 84 vs Day 0 only in the CMA group, in patients with low ADAS-Cog scores ( Figure 3C , Dataset S4). We found that the uric acid levels were significantly lower on Day 84 vs Day 0 only in the CMA group. This reduction was seen both in high-and low-ALT level groups. In contrast, we found that no significantly altered parameters on Day 84 vs Day 0 only in the placebo group ( Figure 3C , Dataset S4).

Furthermore, we observed that the ALT level, total cholesterol and uric acid were significantly improved due to the administration of CMA.

We also measured the level of complete blood count parameters and found that their levels were significantly changed in the CMA group ( Figure 3C , Dataset S4). We found that the levels of platelets and absolute numbers of basophil and neutrophil were significantly lower in the CMA group on Day 84 vs Day 0. In contrast, we found that the levels of monocytes were significantly increased in the CMA group on Day 84 vs Day 0. There were significant decreases in the inflammatory parameters in the patients with high ADAS-Cog scores on Day 84 ( Figure 3C , Dataset S4). Our analysis suggested that the administration of CMA improved the clinical parameters in parallel to the cognitive functions in AD.

Treatment response variability and clinical heterogeneity in AD are well documented in the literature. We observed interindividual variability in responses to CMA as well as in clinical measures. Therefore, we hypothesized that some of the patients would respond better to CMA than others and that clinical measurements could define these subsets.

To determine whether alanine transferase (ALT), a marker for liver damage, could indicate a better response to CMA, we stratified the patients into high and low ALT groups by the median value of ALT of all patients on Day 0. As shown in Figure 4A , the patients of the CMA group with low ALT achieved a significant improvement in ADAS-Cog score over different time points, while the patients in the placebo group had no improvement. In contrast, the patients of the CMA group with high ALT levels also exhibited an improved (i.e., decreased) ADAS-Cog score, but the degree of change was not as much as the patients in the CMA group with low ALT levels. Moreover, patients in the placebo group with high ALT levels also achieved an improved ADAS-Cog score. Thus, these results suggest that the patients with low ALT levels are more responsive to CMA.

We repeated this stratification for each blood parameter to determine the patient conditions in which CMA produces the greatest response ( Figure 4B ). In addition to low ALT, we identified high ALP, low GGT, high HCT, high HbA1c, high insulin, high uric acid, high ADAS-Cog, high basophil count, and high red blood cell count as indicators for better responsiveness to CMA. We also found that individuals who do not drink alcohol or smoke also respond better to CMA.

We first analyzed the plasma levels of serine, carnitine, NR, and cysteine byproducts. CMA administration increased the plasma levels of metabolic activators on Day 84 vs Day 0 in the CMA group ( Figure 5A , Dataset S5). Moreover, the plasma levels of NR, 1methylnicotinamide, nicotinurate, N1-methyl-2-pyridone-5-carboxamide and nicotinamide (associated with NR and NAD+ metabolism); of serine, glycine and sarcosine (associated with serine and glycine metabolism); and of deoxycarnitine and carnitine (associated with . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 20, 2021. ; https://doi.org/10.1101/2021.07.14.21260511 doi: medRxiv preprint carnitine metabolism) were significantly higher in the CMA group on Day 84 compared to Day 0.

Next, we investigated the relationship with the plasma level of administrated metabolic activators and other metabolites. We analyzed 195 of the most significantly correlated plasma metabolites with serine, L-carnitine, NR, and cysteine (Dataset S6). We found two clusters of metabolites that are significantly correlated with cysteine only or serine, carnitine and NR.

We observed that cysteine had a different plasma changes compared to the other three metabolic activators as has been reported in previous clinical trials 24, 30 .

We identified the significantly ( N-acetyl aspartate (NAA) is one of the most abundant brain metabolites and its reduced plasma levels are associated with brain tissue damage. Previous research revealed the importance of NAA to maintain energy metabolism in the central nervous system 31 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 20, 2021. ;  Increased plasma levels of metabolites in the kynurenine pathway are associated with AD severity 33 . In our study, we found that plasma levels of kynurenate and 8-methoxykynurenate were significantly lower on Day 84 vs Day 0 in the CMA group ( Figure 5B , Dataset S5).

Reduction in the plasma level of kynurenate was positively correlated with plasma serine levels (Dataset S6). Kynurenate, which has a prooxidant effect, is the product of the tryptophan degradation pathway. Its aerobic irradiation produces superoxide radicals and leads to cytochrome C reduction 35 . It has been reported that increased levels of kynurenine lead to cell death through the reactive oxygen species (ROS) pathway in nature killer (NK) cells 36 and lower blood pressure in systemic inflammation 37 .

Emerging evidence indicates a link between the abnormal kidney function and AD, but the potential impact of kidney on cognitive impairment is still undetermined 38 

Multi-omics data integrations have been proven to give novel insights and a more holistic view of the human body, in both healthy and disease states 41 . In this study, we generated an integrative multi-omics network using metabolomics and proteomics data, coupled with detailed clinical variables, to understand the functional relationships between analytes from the same and different omics data types. We generated the network using the method used in iNetModels 42 , to which we also deposited our network. The network consists of 937282 edges from 2273 nodes (36.3% network density, Dataset S8).

We extracted a sub-network to highlight the interactions between the metabolic activators, cognitive function (ADAS-Cog), two highlighted proteins (OSM and PSPN), and their top neighbors ( Figure 6C ). From the sub-network, ADAS-Cog was shown to be negatively . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 20, 2021. ; https://doi.org/10.1101/2021.07.14.21260511 doi: medRxiv preprint associated with carnitine (and its derivatives) and nicotinamide associated metabolites, where the metabolic cofactors were negatively associated with fatty acid and histidine metabolites.

Finally, we observed that, among others, OSM and PSPN were positively associated with immune and cell cycle-related proteins.

Subsequently, we performed centrality analysis to identify the most central analytes in the networks. The top 20 most central metabolites were dominated by amino acid metabolites (tryptophan, glutamate, and branched-chain amino acid metabolism) and lipid metabolites (androgenic steroid pathway), where top proteins were related to, among others, short-and long-term memory (CALB1), lipid metabolism (PLA2G10), and immune response (SELPLG, CLEC4D, and LGALS7). Furthermore, we performed community analysis within the network using the Leiden algorithm. We discovered 3 modules that showed significant interaction among the members. In cluster-0, the biggest clusters, the top nodes were related to tryptophan metabolism (indoleacetate), fatty acid metabolism (3-hydroxyoctanoate), and steroid metabolism (11-ketoetiocholanolone glucuronide and 11-beta-hydroxyetiocholanolone glucuronide). Moreover, we found 2 top proteins in the same cluster, ACTA2 and IGFBP1, that have been associated with AD 43, 44 . In cluster-1, the top nodes were associated with is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 20, 2021. ; https://doi.org/10.1101/2021.07.14.21260511 doi: medRxiv preprint animals treated with an oral administration of CMAs. Thus, the present study suggests an attractive therapeutic regime for improving mitochondrial dysfunction in Alzheimer Disease patients.

The metabolomics data confirmed the expected biological outcomes of CMA treatment.

Levels of plasma nicotinamide and related metabolites increased, suggesting that NR provided sufficient substrate for mitochondrial fatty acid oxidation. In addition to its role as a cellular metabolite, NAD+ functions as an essential cofactor for the DNA repair protein PARP1 17 . Hyperactivation of PARP1 and decreased NAD+ have been already identified in the brains of patients with AD 45, 46 . Serine plasma levels also increased, suggesting that CMA treatment improves the serine deficiency associated with AD. For instance, a recent study showed that the adenosine triphosphate (ATP)-reducing the effect of glucose hypometabolism was restored with oral serine supplementation, suggesting the potential use of oral serine as a ready-to-use therapy for AD 47 . The exact mechanism of action also applies to cysteine. As a glutathione precursor, cysteine is even more specific in acting as an antioxidant and antiinflammatory agent, maintaining the mitochondrial energetic homeostasis and key neurotransmitter systems, such as glutamate, involved in learning and memory 48, 49 .

Accordingly, NAC has been tested as a medication in AD and found to exhibit effects suggestive of future potential use as an alternative medication 50 Clinically, when patients with AD were stratified by high and low ADAS-Cog scorer, we observed that patients with lower ADAS-Cog scores in the placebo group also showed improved cognitive function similar to CMA group. However, for the patients with higher ADAS-Cog scores, cognitive function was not improved in the placebo group, while a positive effect was observed for the patients treated with metabolic activators. This is . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 20, 2021. particularly interesting, since this patient group lacks current therapeutic regimes, except for palliative support. Apart from clinical severity, we also observed that various clinical variables were also related to the treatment response. For example, patients with low ALT, who did not drink alcohol or smoke, and who had signs of an increased metabolic load (i.e., increased HbA1c and insulin levels) or impaired CBC values responded better to treatment.

Additionally, the treatment significantly improved the altered metabolic and CBC parameters described above.

In addition, the levels of tryptophan metabolites, including kynurenate, kynurenine, and tryptophan betaine, decreased significantly after CMA treatment. Increased levels of these metabolites were previously shown to be associated with increased neurodegeneration and clinical cognitive impairment through an increased oxidative load and the formation of neurofibrillary tangles (NFTs) 57, 58 . For instance, recent data showed a synergistic relationship between β -amyloid 1-42 and enzymatic activations of the tryptophan kynurenine pathway, resulting in increased oxidative stress, which may be associated with the formation of NFTs and senile plaque development 59 . Also, one recent study revealed that tryptophan-2,3dioxygenase (TDO) was highly expressed in the brains of patients with AD and co-localized with quinolinic acid, NFTs, and amyloid deposits in the hippocampus of post-mortem brains of patients with AD 60 .

We also observed significantly increased levels of NAA, sarcosine, methionine, cysteine, and S-adenosylmethionine (SAM) and decreased levels of histidine, tryptophan quinolate, and urea cycle metabolites, which play a critical role in cognitive and mitochondrial functions. For instance, increased NAA may provide an additional energy source for intercellular metabolite trafficking during the neurodegenerative process, especially when glucose metabolism is downregulated 31 . Similarly, increased sarcosine levels may boost cognition, as previously shown in patients with schizophrenia, in which oxidative damage and impaired glucose metabolism play key roles 61 . In addition, decreased histidine metabolism and other decreased markers, such as homocysteine and S-adenosylhomocysteine (SAH) found in our treatment group, have been already shown to slow the cognitive ageing process appropriately downregulated 62 . For instance, increased plasma homocysteine levels are a known risk factor for AD, whereas a low leucine and arginine diet yield beneficial cognitive effects 63 .

Unexpectedly, CMA rapidly lowered uric acid and associated metabolites levels. Uric acid stimulates inflammation either directly or by activating NLRP3 inflammasomes 64 . Although the extent to which uric acid reduction contributed to the regression in cognitive impairment . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 20, 2021. ; https://doi.org/10.1101/2021.07.14.21260511 doi: medRxiv preprint is unclear, it likely that it is linked to the improvement in the metabolic homeostasis. A good example is a recent clinical study showing increased urea metabolism in patients with AD 65 .

Accordingly, decreased taurine levels and urea metabolites are associated with a diminished risk of dementia 66 . The majority of clinical study findings collectively agree with our results, showing significantly dysregulated baseline metabolites, which normalized with treatment.

Of note, to date, a few studies aimed to identify global changes in metabolites and metabolic pathways in AD 15, 67, 68 . Among these, some studies highlighting that lipid dysfunction also plays an important role in the pathophysiology of AD 69 . In terms of lipid metabolism, significant differences in the levels of some compounds have been observed in patients with AD. Despite some discrepant trends in cross-sectional studies examining the levels of lipids in AD patients 70, 71 , the plasma levels of sphingolipids, sphingomyelins 72,73 , acylcarnitines 74 and phosphatidylcholines(PC) 75-77 exhibited statistically lower concentrations in patients with AD, even in the preclinical stages of the disease 18 . In addition, a significant correlation among different lipid metabolites, tau and amyloid pathology, brain atrophy and cognitive decline was observed in a recent human AD study 18 . An autopsy study of frontal cortex metabolites from patients with AD showed that impaired glycerophospholipid metabolism was involved in six central metabolic pathways reported to be altered in the disease 78 . In brief, we observed significantly increased post-therapeutic levels of lipid metabolites, previously reported to decrease in patients with AD, including sphingomyelin, carnitine and carnitine-related byproducts.

Despite insufficient clinical AD data concerning cholesterol metabolites and dicarboxylic acids (DCAs), we observed significantly lower levels of these metabolites after CMA treatment 79 . Levels of pregnanediol, a metabolite of pregnenolone, and DCAs, end-products of β -or omega oxidation, which were observed as decreased in the present study, were previously reported to be lower in the urine of patients with AD 80 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 20, 2021. ; https://doi.org/10.1101/2021.07.14.21260511 doi: medRxiv preprint

The proteomic analysis in this study revealed significant alteration in levels of several critical proteins that play an essential role in the pathogenesis of AD. For instance, levels of MertK 84,85 , EGFR 86, 87 , oncostatin [88] [89] [90] [91] [92] , PAD4 93,94 , LTGF [95] [96] [97] [98] [99] , and TPO 100 , known as a strong inducer of neuro-inflammation, amyloid production and apoptosis, decreased. In contrast, proteins with neuroprotective and pro-cognitive properties, such as Klotho 101,102 and ST3GAL1 103 , increased after CMA treatment. More interestingly, the majority of the analyzed proteins were also found to be significantly altered in recent human AD studies [95] [96] [97] [98] [99] [104] [105] [106] [107] [108] [109] [110] .

KlothoB levels were also significantly altered after CMA treatment, consistent with their neuroprotective role as a cofactor and neurotrophic factor. In this context, recent studies have shown that KlothoB indirectly regulates glucose and energy metabolism through F2F1, expressed in certain areas of the brain involved in learning and memory 109 . Moreover, GABA signaling has also been shown to play a critical role in mediating the detrimental effects of increased dihydroxybutyrate levels in the progression of MCI 111 . Interestingly, our metabolomic study indicated decreased post-therapeutic dihydroxybutyrate levels. Although the exact pathways involved in the metabolic generation of DHBA are still far from clear, it has been hypothesized that dihydroxybutyrate levels may be a compensatory response to increased cellular stress secondary to compromise of the Krebs cycle function, creating an alternative energy production pathway in AD 111 . This represents indirect evidence to suggest that our treatment exhibits an energetic regulatory function.

Although there has been no direct evidence relating plasma ascorbic acid (AA) levels to the pathogenesis of AD, our finding of decreased plasma levels after CMA may be related to increased brain concentrations and central consumption of ascorbic acid in cognitively improved patients with AD. In this respect, and contrast to other metabolites, a direct transmission from the periphery to the brain suggested that AA might play a 'nourishing' role in the brain. A direct correlation between brain levels of AA and dementia was eventually confirmed by a recent study showing that a high CSF: plasma AA ratio was a marker of a "healthier" brain, better able to cope with the neurodegenerative process in AD 112 .

However, despite these promising human data, plasma levels of several proteins in AD observed after CMA treatment in the present study were inconsistent with their established beneficial role under experimental conditions. For example, PSP, which decreased in the present study, is a novel neurotrophic factor exhibiting significant similarities to GDNF by exerting intense neurotrophic activity, specifically on central neurons 113, 114 . Such discrepancies are not easily explained, even if the different results obtained in peripheral . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 20, 2021. ; https://doi.org/10.1101/2021.07.14.21260511 doi: medRxiv preprint blood can be correlated with improved clinical status. A finding of decreased or increased post-therapeutic levels of these proteins in patients with AD may reflect a treatment-related alteration in their cellular processing in the central nervous system, resulting in variability in protein production and/or degradation in peripheral blood. In addition, controversial data have been reported regarding the concentrations of most of these proteins in patients with AD 72, [115] [116] [117] [118] . Also, due to the high heterogeneity of clinical cohorts and the restricted number of patients, the reproducibility of previous proteomics studies' results is noticeably low.

Despite these inconsistencies, our therapeutic data fits well with recent ROSMAP transcriptomic data in AD patients, showing impaired glycolysis, urea cycle, and fatty acid metabolism that was considerably normalized after the CMA treatment. For instance, our transcriptomic analysis showed increased expressions of pyruvate dehydrogenase kinase 4 (PDK4), carnitine palmitoyltransferase (CPT1A) and hexokinase 2 (HK2). It decreased expressions of acyl-CoA dehydrogenases (ACADs), ATP synthase (ATP5MGL), and acetyland acyltransferases (GCNT7, MBOAT4, GALNT17) which have been already reported to link/associate with critical energetic deficiencies due to decreased glycolysis and lipid oxidation metabolism. Consistent with the above-mentioned expression levels, we observed increased metabolites in the cytosol, including carnitine, spermine, serine, alanine, glucose 6phosphate, and acyl-CoA responsible for glycolytic and lipid metabolism-related energetic cascades. Also, our animal data confirmed the beneficial effects of our CMA, showing the most substantial impacts on hyperemia, neuronal degeneration and necrosis in HFD animals.

In evaluating the correlations between each cofactor (used in the present study for therapeutic purposes) and clinical, metabolic, and proteomic parameters, we identified significant correlations between serine, carnitine, cysteine, and nicotinamide levels and improved peripheral blood parameters, such as liver function, CBC, and glycated hemoglobin (HbA1c), which are relevant to the pathogenesis of AD. Accordingly, improved ADAS-Cog scores were also associated with changes in serum serine and carnitine, which fit well with their well-known pro-cognitive and energy-boosting effects. Similar results were also observed for metabolomic and proteomic data. The majority of the cofactors exhibited significant correlations with improved metabolites and proteins (either increased or decreased) relative to a slower degeneration process in AD. It is worth mentioning here that that two of the proteins, OSM and PSPN, most strongly associated with other beneficial protein metabolites, were also related to several critical amino acid alterations, such as spermidine and hypotaurine, which . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 20, 2021. ; https://doi.org/10.1101/2021.07.14.21260511 doi: medRxiv preprint may suggest a metabolic shift from the protein to amino acid metabolism to compensate the energy deficit reported in AD.

A few limitations of the study need to be considered. First, the treatment effect was assessed only by omics-based methods and clinical evaluation. Thus, our findings warrant a clinical trial with neuroimaging analysis to delineate the impact of CMA on functional and structural brain alterations. Second, the link between systemic and CNS alterations and their relations to the AD pathology, i.e., amyloid and tau aggregation, has not been evaluated. Thus, further amyloid or tau-based neuroimaging combined with CSF evaluation should be pursued.

In summary, the human phase 2 clinical study supports the data from animal models and genome-scale metabolic modelling suggesting that oral administration of metabolic activators can improve the mitochondrial dysfunction in AD patients. The safety profile of metabolic activators in these patients was consistent with the results of our previous one-day calibration study and clinical trials, including only a single component of the CMA 20 . Our present study showed that CMA was safe and well-tolerated in patients with AD, and no major safety concerns were identified. Importantly, CMA improved cognition and serum markers in these patients after only 12 weeks of treatment. These findings suggest that targeting multiple pathways by metabolic activators is a potentially effective therapeutic strategy for AD.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 20, 2021. ; https://doi.org/10.1101/2021.07.14.21260511 doi: medRxiv preprint

The mRNA expression profiles of 629 AD and 704 control samples were obtained from the Religious Orders Study and Rush Memory Aging Project (ROSMAP) datasets [26] [27] [28] . The data has been normalized by quantile scaling, TMM normalization, Pareto scaling, and then limma removeBatchEffect 119 . DESeq2 120 was used to identify the differentially expressed genes (DEGs) with uniform size factors. Ensembl Biomart 121 was used to mapping different gene accession IDs or symbols. Gene set enrichment (GSE) was performed by using piano 122 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 20, 2021. ; https://doi.org/10.1101/2021.07.14.21260511 doi: medRxiv preprint

Before surgical procedures, the rats were anesthetized by intraperitoneal administration of ketamine-xylazine (50 mg/kg ketamine and 5mg/kg xylazine) and placed individually in the stereotaxic instrument (Stoelting, Illinois, USA). Stereotaxic coordinates for injection were 0.8 mm posterior to the bregma, 1.5 mm lateral to the sagittal suture and 3.6 mm below the brain surface 126 . Then, 10 microliters of STZ (3 mg/kg, Sigma-Aldrich, Darmstadt, Germany) were injected over 3 min with a Hamilton micro-syringe into the bilateral ventricle. The injection needles were left in place for an additional 2 min to allow diffusion.

For carrying out the treatment experiments, the HFD rats were randomly separated into 9 (Groups 5-10) subgroups (n = 4) and all treated with 3 mg/kg STZ (10 µL, icv). Group 5, treated only with STZ; Group 6, treated with STZ and serine (1000 mg/kg once daily by oral gavage); Group 7, treated with STZ and NAC (300 mg/kg once daily by oral gavage); Group 8, treated with STZ and LCAT (100 mg/kg once daily by oral gavage); Group 9, treated with STZ and NR (120 mg/kg once daily by oral gavage); Group 10, treated with STZ and serine (1000 mg/kg once daily by oral gavage), NAC (300 mg/kg once daily by oral gavage), LCAT (100 mg/kg/day) and NR (120 mg/kg once daily by oral gavage).

The body weight of the rats was recorded each week (Dataset S2). After 5 weeks, all animals were anesthetized with isoflurane and sacrificed. Blood samples were collected from the abdominal aorta and centrifuged at 8000 rpm for 15 min at 4 °C for blood biochemistry analysis using automatic chemical analyzer. The internal organs, including the heart, adipose tissues, liver, kidney, brain, muscle, intestine (duodenum, ileum, jejunum), pancreas, colon and stomach were immediately removed and then snap-frozen in liquid nitrogen and stored at 80˚C.

Liver and brain tissue samples obtained due to the experimental procedure were fixed in 10% buffered formalin solution for 48 hours. Following the routine tissue procedure, the tissues were embedded in paraffin blocks and 4 µm thick sections were taken from each block.

Preparations prepared for histopathological examination were stained with hematoxylin-eosin (HE) and examined with a light microscope (Olympus BX51, Germany). According to histopathological findings sections were evaluated by independent pathologist and scored as absent (-), very mild (+), mild (++), moderate (+++) and severe (++++).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 20, 2021. ; https://doi.org/10.1101/2021.07.14.21260511 doi: medRxiv preprint

Tissue sections taken on the adhesive (poly-L-Lysin) slides for immunoperoxidase examination were deparaffinized and dehydrated. After washing, the tissues with suppressed endogenous peroxidase activity in 3% H 2 O 2 were boiled in antigen retrieval solution. To prevent nonspecific background staining in the sections, protein block compatible with all primary and secondary antibodies was dropped and incubated for 5 minutes. Caspase 3 (cat no:sc-56053 dilution ratio:1/100 US) for liver tissues and 8-OH-dG (Cat no: sc-66036 dilution ratio: 1/100 US) for brain tissues was used as the primary antibody. 3-3' Diaminobenzidine (DAB) chromogen was used as chromogen, and according to their immunopositivity, sections were evaluated by independent pathologist and scored as absent (-), very mild (+), mild (++), moderate (+++) and severe (++++).

Tissue sections taken on the adhesive (poly-L-Lysin) slides for immunoperoxidase examination were deparaffinized and dehydrated. After washing, the tissues with suppressed endogenous peroxidase activity in 3% H 2 O 2 were boiled in antigen retrieval solution. To is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 20, 2021. ;  (ZEISS Germany) by an independent pathologist and, according to their immunopositivity evaluated as absent (-), very mild (+), mild (++), moderate (+++) and severe (++++).

Patients for this randomized, double-blinded, placebo-controlled, phase 2 study were recruited at the Faculty of Medicine, Alanya Alaaddin Keykubat University, Antalya, Turkey and Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey. Written informed consent was obtained from all participants before the initiation of any trial-related procedures.

The safety of the participants and the risk-benefit analysis was overseen by an independent external data-monitoring committee. The trial was conducted following Good Clinical Practice guidelines and the principles of the Declaration of Helsinki. The ethics committee approved the study of Istanbul Medipol University, Istanbul, Turkey, and retrospectively registered at https://clinicaltrials.gov/ with Clinical Trial ID: NCT04044131.

Patients were enrolled in the trial if they were over 50 years of age with mild to moderate AD according to ADAS-cog (AD Assessment Scale-cognitive subscale; ADAS≥12) and the Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB; CDR≤2). Patients who had a history of stroke, severe brain trauma, toxic drug exposure were excluded. The main characteristics of the patients are summarized in Dataset S3. The inclusion, exclusion, and randomization criteria are described in detail in the Supplementary Appendix.

Patients were randomly assigned to receive CMA or placebo (2:1). Patient information (patient number, date of birth, initials) was entered into the web-based randomization system, and the randomization codes were entered into the electronic case report form. All clinical staff were blinded to treatment, as were the participants. The limit of detection, determined for each of the assays, was defined as three standard deviations above the negative control (background).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

The patient groups with low and high levels of each clinical parameter were established based on the median score for that clinical parameter across all patients on Day 0. Patients scoring at or below the median were placed in the low group; patients scoring above the median were placed in the high group. ADAS-Cog scores were measured over different time points and statistical significance was tested between time points by using a paired t-test. Clinical parameters were deemed informative for the response to CMA if exactly one group (low or high) exhibited more statistically significant changes in ADAS-Cog in the CMA group than in the placebo group.

Paired t-test was used to identify the differences in clinical parameters between time points and one-way ANOVA was used to find the shifts between CMA and placebo groups at each time point. For analysis of plasma metabolomics, we removed the metabolite profiles with more than 50% missing values across all samples. Metabolite changes between time points were analyzed by paired t-test. Metabolite changes between CMA and placebo groups were analyzed by one-way ANOVA. Missing values were removed in pairwise comparison. The pvalues were adjusted by Benjamini & Hochberg method. Metabolites with a false-discovery rate of 5% were considered statistically significant. Two-sided Student's t-test was used for statistical analyses of plasma parameters in animal model, statistical significance was considered p < 0.05.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 20, 2021. ; https://doi.org/10.1101/2021.07.14.21260511 doi: medRxiv preprint For analysis of plasma proteomics, we removed the protein profiles with more than 50% missing values across all samples. Pair t-test was used to identify the changes between time points and one-way ANOVA was used to identify the changes between different groups. p<0.01 was considered statistically significant. Spearman correlation analysis was used to analyze the association between CMAs and clinical parameters or metabolomics or proteomics.

Multi-omics network was generated based on the Spearman correlations and the significant associations (FDR < 0.05) are presented. The analyses were performed with SciPy package in Python 3.7. Centrality analysis on the network was performed using iGraph Python. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 20, 2021. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 20, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 20, 2021. ; https://doi.org/10.1101/2021.07.14.21260511 doi: medRxiv preprint represents the neighbors of the CMA, including serine, carnitine, nicotinamide and cysteine, and ADAS-Cog scores. Only analytes that are significantly altered in CMA Day 84 vs Day 0 are highlighted.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 20, 2021. ; https://doi.org/10.1101/2021.07.14.21260511 doi: medRxiv preprint

Dataset S1. Transcriptomic analysis of Alzheimer's disease brain tissue samples in ROSMAP datasets. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 20, 2021. ; Figure 1 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity (which was not certified by peer review) CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity (which was not certified by peer review)

In vivo modification of Abeta plaque toxicity as a novel neuroprotective lithium-mediated therapy for Alzheimer's disease pathology

RNA and Oxidative Stress in Alzheimer's Disease: Focus on microRNAs

A systems biology approach for studying neurodegenerative diseases

A biochemical and functional characterization of diet-induced brain insulin resistance

Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums

Ribosylation triggering Alzheimer's disease-like Tau hyperphosphorylation via activation of CaMKII

Effects of long-term treatment with pioglitazone on cognition and glucose metabolism of PS1-KI, 3xTg-AD, and wild-type mice

Metabolic Profiling of Female Tg2576 Mouse Brains Provides Novel Evidence Supporting Intranasal Low-Dose Pioglitazone for Long-Term Treatment at an Early Stage of Alzheimer's Disease

The amyloid hypothesis on trial

Alzheimer Research, Glucose Metabolism Moves to Center Stage

Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies

Universal Glia to Neurone Lactate Transfer in the Nervous System: Physiological Functions and Pathological Consequences

Aging-associated changes in hippocampal glycogen metabolism in mice. Evidence for and against astrocyte-toneuron lactate shuttle

Alzheimer's disease drug development pipeline: 2020

Alzheimer's disease-like pathology has transient effects on the brain and blood metabolome

Global Metabolic Shifts in Age and Alzheimer's Disease Mouse Brains Pivot at NAD+/NADH Redox Sites

NAD+ supplementation normalizes key Alzheimer's features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency

Metabolic network failures in Alzheimer's disease: A biochemical road map

Alzheimer's disease in the omics era

The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against non-alcoholic fatty liver disease

The Potential Use of Metabolic Cofactors in Treatment of NAFLD

Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease

Systems biology in hepatology: approaches and applications

Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19

An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans

A survey of genetic human cortical gene expression

Genetic control of human brain transcript expression in Alzheimer disease

A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer's disease

Integration of clinical data with a genome-scale metabolic model of the human adipocyte

Combined Metabolic Activators Reduces Liver Fat in Nonalcoholic Fatty Liver Disease Patients. medRxiv

N-Acetylaspartate reductions in brain injury: impact on post-injury neuroenergetics, lipid synthesis, and protein acetylation

Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia

Kynurenine pathway metabolites in humans: disease and healthy States

Is L-methionine a trigger factor for Alzheimer's-like neurodegeneration?: Changes in Aβ oligomers, tau phosphorylation, synaptic proteins, Wnt signaling and behavioral impairment in wild-type mice

Tryptophan-kynurenine pathway is dysregulated in inflammation, and immune activation

Oxidative Stress and the Kynurenine System, with a Focus on Ageing and Neuroprotection

Vasorelaxing Action of the Kynurenine Metabolite, Xanthurenic Acid: The Missing Link in Endotoxin-Induced Hypotension?

A Novel Perspective Linkage Between Kidney Function and Alzheimer's Disease

Metabolomic Profile Predicts Development of Microalbuminuria in Individuals with Type 1 Diabetes

Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease

Multi-omics approaches to disease

iNetModels 2.0: an interactive visualization and database of multi-omics data

Alpha-Smooth Muscle Actin mRNA and Protein Are Increased in Isolated Brain Vessel Extracts of Alzheimer Mice

Increased Cerebrospinal Fluid Level of Insulin-like Growth Factor-II in Male Patients with Alzheimer's Disease

Bioenergetic Impairment in Animal and Cellular Models of Alzheimer's Disease: PARP-1 Inhibition Rescues Metabolic Dysfunctions

PARP-1 involvement in neurodegeneration: A focus on Alzheimer's and Parkinson's diseases

Impairment of Glycolysis-Derived l-Serine Production in Astrocytes Contributes to Cognitive Deficits in Alzheimer's Disease

N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities

Overview on the Effects of N-Acetylcysteine in Neurodegenerative Diseases

Evaluation of the Neuroprotective Potential of N-Acetylcysteine for Prevention and Treatment of Cognitive Aging and Dementia

Preventive Role of L-Carnitine and Balanced Diet in Alzheimer's Disease

Role of carnitine in disease

Serum Levels of Acyl-Carnitines along the Continuum from Normal to Alzheimer's Dementia

L-carnitine for cognitive enhancement in people without cognitive impairment

Alzheimer's disease: the pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspective of patients and practitioners

Acetyl-Lcarnitine (carnicetine) in the treatment of early stages of Alzheimer's disease and vascular dementia

The involvement of astrocytes and kynurenine pathway in Alzheimer's disease

Stress-related regulation of the kynurenine pathway: Relevance to neuropsychiatric and degenerative disorders

A beta 1-42 induces production of quinolinic acid by human macrophages and microglia

Expression of tryptophan 2,3-dioxygenase and production of kynurenine pathway metabolites in triple transgenic mice and human Alzheimer's disease brain

Oxidative-Antioxidant Imbalance and Impaired Glucose Metabolism in Schizophrenia

Plasma homocysteine as a risk factor for dementia and Alzheimer's disease

Amino Acid Catabolism in Alzheimer's Disease Brain: Friend or Foe

Soluble Uric Acid Activates the NLRP3 Inflammasome

Is the urea cycle involved in Alzheimer's disease?

Association of amine biomarkers with incident dementia and Alzheimer's disease in the Framingham Study

Untargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer's disease

Plasma metabolite profiles of Alzheimer's disease and mild cognitive impairment

Involvement of Lipids in Alzheimer's Disease Pathology and Potential Therapies

Systemic and central nervous system metabolic alterations in Alzheimer's disease

Prospective associations of plasma phospholipids and mild cognitive impairment/dementia among African Americans in the ARIC Neurocognitive Study

Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics

Plasma phospholipids and prevalence of mild cognitive impairment and/or dementia in the ARIC Neurocognitive Study (ARIC-NCS)

Medium-chain plasma acylcarnitines, ketone levels, cognition, and gray matter volumes in healthy elderly, mildly cognitively impaired, or Alzheimer's disease subjects

Targeted Metabolomic Analysis of Soluble Lysates from Platelets of Patients with Mild Cognitive Impairment and Alzheimer's Disease Compared to Healthy Controls: Is PC aeC40:4 a Promising Diagnostic Tool?

Blood metabolite markers of cognitive performance and brain function in aging

Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease

Unbiased Metabolomic Investigation of Alzheimer's Disease Brain Points to Dysregulation of Mitochondrial Aspartate Metabolism

Urine dicarboxylic acids change in pre-symptomatic Alzheimer's disease and reflect loss of energy capacity and hippocampal volume

Urinary metabolic phenotyping for Alzheimer's disease

Saturated dicarboxylic acids as products of unsaturated fatty acid oxidation

Neuroactive steroid effects on cognitive functions with a focus on the serotonin and GABA systems

Bile acids regulate cysteine catabolism and glutathione regeneration to modulate hepatic sensitivity to oxidative injury

Sulforaphane rescues amyloid-β peptidemediated decrease in MerTK expression through its anti-inflammatory effect in human THP-1 macrophages

Receptor Pathways at the Crossroads of Neuroinflammation and Neurodegeneration

PI3 kinase signaling is involved in Abeta-induced memory loss in Drosophila

Epidermal growth factor receptor is a preferred target for treating Amyloid-βinduced memory loss

Inflammatory cytokines in the brain: does the CNS shape immune responses?

Oncostatin M and the interleukin-6 and soluble interleukin-6 receptor complex regulate alpha1-antichymotrypsin expression in human cortical astrocytes

Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes

Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease

The molecular pathology of Alzheimer's disease

Peptidyl Arginine Deiminases and Neurodegenerative Diseases

Neuronal PAD4 expression and protein citrullination: possible role in production of autoantibodies associated with neurodegenerative disease

Association of a polymorphism of the transforming growth factor-beta1 gene with cerebral amyloid angiopathy

Role of the APP promoter in Alzheimer's disease: cell type-specific expression of the beta-amyloid precursor protein

Analysis of genetic polymorphisms in the transforming growth factor-beta1 gene and the risk of Alzheimer's disease

Transforming growth factor-beta-induced transcription of the Alzheimer beta-amyloid precursor protein gene involves interaction between the CTCF-complex and Smads

Transforming growth factor-beta 1 potentiates amyloid-beta generation in astrocytes and in transgenic mice

A hematopoietic growth factor, thrombopoietin, has a proapoptotic role in the brain

Plasma Klotho concentration is associated with the presence, burden and progression of cerebral small vessel disease in patients with acute ischaemic stroke

Klotho at the Edge of Alzheimer's Disease and Senile Depression

The significance of sialylation on the pathogenesis of Alzheimer's disease

Hematopoietic prostaglandin D synthase and DP1 receptor are selectively upregulated in microglia and astrocytes within senile plaques from human patients and in a mouse model of Alzheimer disease

Increased intrathecal levels of the angiogenic factors VEGF and TGFbeta in Alzheimer's disease and vascular dementia

Serum cytokine levels in patients with Alzheimer's disease

δ scores predict mild cognitive impairment and Alzheimer's disease conversions from nondemented states

Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort

Therapeutic Approaches to Alzheimer's Type of Dementia: A Focus on FGF21 Mediated Neuroprotection

Lower Plasma Klotho Concentrations Are Associated with Vascular Dementia but Not Late-Onset Alzheimer's Disease

Hypoxia and GABA shunt activation in the pathogenesis of Alzheimer's disease

Ascorbic acid and rates of cognitive decline in Alzheimer's disease

Persephin, a Novel Neurotrophic Factor Related to GDNF and Neurturin

The GDNF family members neurturin, artemin and persephin promote the morphological differentiation of cultured ventral mesencephalic dopaminergic neurons

New screening approach for Alzheimer's disease risk assessment from urine lipid peroxidation compounds

Plasma levels of neuropeptides in Alzheimer's disease

A blood-based, 7-metabolite signature for the early diagnosis of Alzheimer's disease

Plasma sphingolipid changes with autopsy-confirmed Lewy Body or Alzheimer's pathology

limma powers differential expression analyses for RNA-sequencing and microarray studies

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Enriching the gene set analysis of genome-wide data by incorporating directionality of gene expression and combining statistical hypotheses and methods

The RAVEN toolbox and its use for generating a genome-scale metabolic model for Penicillium chrysogenum

Systems analysis reveals ageing-related perturbations in retinoids and sex hormones in Alzheimer's and Parkinson's diseases. bioRxiv

KEGG Mapper for inferring cellular functions from protein sequences

A stereotaxic atlas of the rat brain